NO20081723L - Assosiasjon av beta 3 reseotoragonist og monoamin gjenopptaksinhibator, farmasoytisk sammensetting inneholdende samme og terapeutisk anvendelse derav - Google Patents

Assosiasjon av beta 3 reseotoragonist og monoamin gjenopptaksinhibator, farmasoytisk sammensetting inneholdende samme og terapeutisk anvendelse derav

Info

Publication number
NO20081723L
NO20081723L NO20081723A NO20081723A NO20081723L NO 20081723 L NO20081723 L NO 20081723L NO 20081723 A NO20081723 A NO 20081723A NO 20081723 A NO20081723 A NO 20081723A NO 20081723 L NO20081723 L NO 20081723L
Authority
NO
Norway
Prior art keywords
association
agonist
pharmaceutical composition
reseotor
therapeutic use
Prior art date
Application number
NO20081723A
Other languages
English (en)
Inventor
Guy Griebel
Jeanne Stemmelin
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20081723L publication Critical patent/NO20081723L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives assosiasjonen av minst én ß3 adrenergisk reseptoragonist (eller ß3 agonist) (I) med en monoamingjenopptaksinhibitor. Det beskrives videre et farmasøytisk preparat omfattende oppfinnelsens assosiasjon og dennes terapeutiske anvendelse.
NO20081723A 2005-09-19 2008-04-07 Assosiasjon av beta 3 reseotoragonist og monoamin gjenopptaksinhibator, farmasoytisk sammensetting inneholdende samme og terapeutisk anvendelse derav NO20081723L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0509528A FR2890862B1 (fr) 2005-09-19 2005-09-19 Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique.
PCT/FR2006/002125 WO2007034056A1 (fr) 2005-09-19 2006-09-18 ASSOCIATION D'AGONISTE AUX RECEPTEURS ß3 ET D'INHIBITEURS DE LA RECAPTURE DE MONOAMINES, COMPOSITION PHARMACEUTIQUE LA CONTENANT ET SON UTILISATION EN THERAPEUTIQUE

Publications (1)

Publication Number Publication Date
NO20081723L true NO20081723L (no) 2008-05-29

Family

ID=36384391

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081723A NO20081723L (no) 2005-09-19 2008-04-07 Assosiasjon av beta 3 reseotoragonist og monoamin gjenopptaksinhibator, farmasoytisk sammensetting inneholdende samme og terapeutisk anvendelse derav

Country Status (23)

Country Link
US (1) US20080182899A1 (no)
EP (1) EP1928448B1 (no)
JP (1) JP2009508829A (no)
KR (1) KR20080064115A (no)
CN (1) CN101267814A (no)
AR (1) AR055436A1 (no)
AT (1) ATE441407T1 (no)
AU (1) AU2006293801A1 (no)
BR (1) BRPI0616197A2 (no)
CA (1) CA2620235A1 (no)
CR (1) CR9768A (no)
DE (1) DE602006008964D1 (no)
EA (1) EA200800870A1 (no)
EC (1) ECSP088275A (no)
FR (1) FR2890862B1 (no)
IL (1) IL189755A0 (no)
MA (1) MA30002B1 (no)
NO (1) NO20081723L (no)
NZ (1) NZ566310A (no)
TN (1) TNSN08095A1 (no)
TW (1) TW200744571A (no)
WO (1) WO2007034056A1 (no)
ZA (1) ZA200802544B (no)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
FR2669821A1 (fr) * 1990-12-04 1992-06-05 Sanofi Sa Utilisation de phenylethanolaminotetralines pour la preparation de medicaments destines au traitement de la depression.
US5288749A (en) * 1991-12-20 1994-02-22 Abbott Laboratories Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors
US6288749B1 (en) * 1996-11-16 2001-09-11 Altec Lansing Technologies, Inc. Computer system with remote television display
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
FR2826651B1 (fr) * 2001-06-28 2005-09-02 Sanofi Synthelabo Forme cristalline d'une phenylethanolamine, sa preparation et compositions pharmaceutiques la contenant
JP2007505095A (ja) * 2003-09-12 2007-03-08 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー うつ病及び不安障害の治療のためのアルファ−2−デルタリガンド及びssri及び/又はsnriを含む組み合わせ

Also Published As

Publication number Publication date
TNSN08095A1 (en) 2009-07-14
US20080182899A1 (en) 2008-07-31
CA2620235A1 (fr) 2007-03-29
FR2890862A1 (fr) 2007-03-23
DE602006008964D1 (de) 2009-10-15
ECSP088275A (es) 2008-04-28
TW200744571A (en) 2007-12-16
ATE441407T1 (de) 2009-09-15
CN101267814A (zh) 2008-09-17
AR055436A1 (es) 2007-08-22
KR20080064115A (ko) 2008-07-08
WO2007034056A1 (fr) 2007-03-29
MA30002B1 (fr) 2008-12-01
BRPI0616197A2 (pt) 2011-06-14
JP2009508829A (ja) 2009-03-05
IL189755A0 (en) 2008-12-29
CR9768A (es) 2008-09-23
EA200800870A1 (ru) 2008-08-29
EP1928448A1 (fr) 2008-06-11
EP1928448B1 (fr) 2009-09-02
AU2006293801A1 (en) 2007-03-29
ZA200802544B (en) 2009-08-26
NZ566310A (en) 2010-03-26
FR2890862B1 (fr) 2008-01-25

Similar Documents

Publication Publication Date Title
CY1113159T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
DK3219705T3 (da) Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
BRPI0606256A2 (pt) inibidores da enzima 11-beta-hidroxiesteróide desidrogenase tipo i, uso e composição farmacêutica compreendendo os mesmos
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
NO20053965L (no) Fremgangsmate for fremstilling av belagt preparat
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
AU2009303758A8 (en) Benzoquinoline inhibitors of vesicular monoamine transporter 2
ATE390922T1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
NO20072005L (no) Nye heterocykliske amider
BR0315346A (pt) Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente, formulação farmacêutica e utilização de inibidor de re-apreensão de norepinefrina em combinação com antagonista de 5-h2a
SV2005001805A (es) 3-aminopirrolidinas como inhibidores de la captacion de monoamina ref. x-15735
UY29712A1 (es) Sal de derivado de piperidina, composición farmacéutica que la contiene y aplicaciones
EA200801139A1 (ru) Композиция для аэрозольной ингаляции
NO20081723L (no) Assosiasjon av beta 3 reseotoragonist og monoamin gjenopptaksinhibator, farmasoytisk sammensetting inneholdende samme og terapeutisk anvendelse derav
CL2007003396A1 (es) Uso de agomelatina o n-[2-(7-metoxi-1-naftil)etil]acetamida para el tratamiento del sindrome de smith magenis; composicion farmaceutica que contiene agomelatina.
GT200600141A (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos bipolares
MY142260A (en) New association of agomelatine and a noradrenaline reuptake inhibitor, and pharmaceutical compositions containing them
UY29713A1 (es) Sal de derivado de piperidina, composición farmacéutica que la contiene y aplicaciones

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application